Cargando…

Recurrent Intrahepatic Cholangiocarcinoma – Review

Intrahepatic cholangiocarcinoma (ICC) is the second-most common primary liver malignancy after hepatocellular carcinoma. While surgical resection with negative margin is the only curative treatment, ICC has very high rate of recurrence, up to 60-70% after curative resection. We reviewed the current...

Descripción completa

Detalles Bibliográficos
Autores principales: Bekki, Yuki, Von Ahrens, Dagny, Takahashi, Hideo, Schwartz, Myron, Gunasekaran, Ganesh
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8567135/
https://www.ncbi.nlm.nih.gov/pubmed/34746017
http://dx.doi.org/10.3389/fonc.2021.776863
_version_ 1784594170751483904
author Bekki, Yuki
Von Ahrens, Dagny
Takahashi, Hideo
Schwartz, Myron
Gunasekaran, Ganesh
author_facet Bekki, Yuki
Von Ahrens, Dagny
Takahashi, Hideo
Schwartz, Myron
Gunasekaran, Ganesh
author_sort Bekki, Yuki
collection PubMed
description Intrahepatic cholangiocarcinoma (ICC) is the second-most common primary liver malignancy after hepatocellular carcinoma. While surgical resection with negative margin is the only curative treatment, ICC has very high rate of recurrence, up to 60-70% after curative resection. We reviewed the current data available on risk factors for ICC recurrence, recurrence pattern (location and timing), treatment options, and future directions. The risk factors for recurrence include elevated preoperative CA19-9, presence of liver cirrhosis, nodal metastasis, positive margins, and vascular invasion. Understanding different recurrence patterns, timing course, and risk factors for early recurrence is important to tailor postoperative surveillance and select treatment strategies including systemic or locoregional therapy. Re-resection can be considered for a selected patient population at experienced centers, and can yield long-term survival. ICC remains a dismal disease given the high likelihood of recurrence. Advances in our understanding of the genomic landscape of ICC are beginning to identify targetable alterations in ICC in subsets of patients that allow for personalized treatment.
format Online
Article
Text
id pubmed-8567135
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-85671352021-11-05 Recurrent Intrahepatic Cholangiocarcinoma – Review Bekki, Yuki Von Ahrens, Dagny Takahashi, Hideo Schwartz, Myron Gunasekaran, Ganesh Front Oncol Oncology Intrahepatic cholangiocarcinoma (ICC) is the second-most common primary liver malignancy after hepatocellular carcinoma. While surgical resection with negative margin is the only curative treatment, ICC has very high rate of recurrence, up to 60-70% after curative resection. We reviewed the current data available on risk factors for ICC recurrence, recurrence pattern (location and timing), treatment options, and future directions. The risk factors for recurrence include elevated preoperative CA19-9, presence of liver cirrhosis, nodal metastasis, positive margins, and vascular invasion. Understanding different recurrence patterns, timing course, and risk factors for early recurrence is important to tailor postoperative surveillance and select treatment strategies including systemic or locoregional therapy. Re-resection can be considered for a selected patient population at experienced centers, and can yield long-term survival. ICC remains a dismal disease given the high likelihood of recurrence. Advances in our understanding of the genomic landscape of ICC are beginning to identify targetable alterations in ICC in subsets of patients that allow for personalized treatment. Frontiers Media S.A. 2021-10-21 /pmc/articles/PMC8567135/ /pubmed/34746017 http://dx.doi.org/10.3389/fonc.2021.776863 Text en Copyright © 2021 Bekki, Von Ahrens, Takahashi, Schwartz and Gunasekaran https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Bekki, Yuki
Von Ahrens, Dagny
Takahashi, Hideo
Schwartz, Myron
Gunasekaran, Ganesh
Recurrent Intrahepatic Cholangiocarcinoma – Review
title Recurrent Intrahepatic Cholangiocarcinoma – Review
title_full Recurrent Intrahepatic Cholangiocarcinoma – Review
title_fullStr Recurrent Intrahepatic Cholangiocarcinoma – Review
title_full_unstemmed Recurrent Intrahepatic Cholangiocarcinoma – Review
title_short Recurrent Intrahepatic Cholangiocarcinoma – Review
title_sort recurrent intrahepatic cholangiocarcinoma – review
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8567135/
https://www.ncbi.nlm.nih.gov/pubmed/34746017
http://dx.doi.org/10.3389/fonc.2021.776863
work_keys_str_mv AT bekkiyuki recurrentintrahepaticcholangiocarcinomareview
AT vonahrensdagny recurrentintrahepaticcholangiocarcinomareview
AT takahashihideo recurrentintrahepaticcholangiocarcinomareview
AT schwartzmyron recurrentintrahepaticcholangiocarcinomareview
AT gunasekaranganesh recurrentintrahepaticcholangiocarcinomareview